Oxford Nanopore Technologies
plc
Oxford Nanopore and
Plasmidsaurus announce collaboration and multi-year,
multi-million dollar contract expansion
Oxford Nanopore Technologies plc
(LSE: ONT) ("Oxford Nanopore"), the company delivering a new
generation of nanopore-based molecular sensing technology, and
Plasmidsaurus, the LA-based company that introduced overnight
whole-plasmid sequencing, today announce a new strategic
collaboration to advance plasmid sequencing beyond legacy methods,
and an expanded multi-year, multi-million dollar global
contract.
Plasmidsaurus' whole-plasmid
sequencing is used by researchers and industry professionals around
the world for a broad spectrum of applications, from basic research
to industrial applications, gene therapy, vaccine development,
genetic engineering and more. Its sequencing capabilities are based
on Oxford Nanopore's real-time, long-read sequencing technology,
which has enabled Plasmidsaurus to set new standards for quality
and speed, delivering overnight results and richer datasets that
unlock more accurate, comprehensive, and reliable
insights.
The extension of the existing
contract will see the collaboration continue to take share of a
fast-growing estimated $1.5B market opportunity in synthetic
biology as nanopore-based sequencing continues to displace
traditional methods, such as Sanger, for plasmid sequencing.
Founded in 2021, Plasmidsaurus has since opened
nine labs in three countries and is expanding its global network of
660 dropboxes and labs in key biotech hubs, including new locations
in the US, Europe, and Asia. Plasmidsaurus became an Oxford
Nanopore customer in 2021.
As strategic collaborators going
forward, Oxford Nanopore and Plasmidsaurus also intend to
co-develop new technologies, reagents, and applications beyond
plasmid sequencing, including microbial and gene therapy use cases,
to best meet evolving market needs, providing further market share
opportunities.
Gordon Sanghera, CEO of Oxford Nanopore
commented:
"By collaborating with
Plasmidsaurus, we are advancing the fields of synthetic biology and
biotechnology through the unique capabilities of nanopore
technology that are not possible with legacy methods. Our joint
efforts will drive significant market growth and deliver
best-in-class sequencing services to a global audience."
[ENDS]
For further information, please
contact:
Oxford Nanopore Technologies plc
Investors:
ir@nanoporetech.com
Media:
media@nanoporetech.com
Teneo (communications adviser to the
Company)
Tom Murray, Olivia Peters
+44 (0) 20 7353 4200
OxfordNanoporeTechnologies@teneo.com
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal
is to bring the widest benefits to society through enabling the
analysis of anything, by anyone, anywhere. The company has
developed a new generation of nanopore-based sensing technology
that is currently used for real-time, high-performance, accessible,
and scalable analysis of DNA and RNA. The technology is used
in more than 120 countries, to understand the biology of humans,
plants, animals, bacteria, viruses and environments as well as to
understand diseases such as cancer. Oxford Nanopore's technology
also has the potential to provide broad, high impact, rapid
insights in a number of areas including healthcare, food and
agriculture.
Oxford Nanopore devices sequence DNA
and RNA directly and sequence short to ultra-long fragments of DNA,
for a truly comprehensive picture of the genome. Data is streamed
in real-time and can enable rapid insights. The technology is
fully scalable - from pocket-sized to ultra-high throughput
devices.
For more information please
visit: www.nanoporetech.com
Forward-looking statements
This announcement contains certain
forward-looking statements. For example, statements regarding
expected revenue growth and profit margins are forward-looking
statements. Phrases such as "aim", "plan", "expect", "intend",
"anticipate", "believe", "estimate", "target", and similar
expressions of a future or forward-looking nature should also be
considered forward-looking statements. Forward-looking statements
address our expected future business and financial performance and
financial condition, and by definition address matters that are, to
different degrees, uncertain. Our results could be affected by
macroeconomic conditions, the COVID-19 pandemic, delays in our
receipt of components or our delivery of products to our customers,
suspensions of large projects and/or acceleration of large products
or accelerated adoption of pathogen surveillance. These or other
uncertainties may cause our actual future results to be materially
different than those expressed in our forward-looking
statements.